Gene Logic/Oncormed
This article was originally published in The Gray Sheet
Executive Summary
Firms ink definitive agreement under which Gene Logic acquires Oncormed in a stock deal valued at up to $38 mil. Oncormed, which uses proprietary genomics technologies and software to characterize genes to establish clinical relevance and to profile patients for pharmacogenomic and therapeutic purposes, had handed over its BRCA1/BRCA2 breast and ovarian genetic testing business to Myriad Genetics under a May patent infringement settlement ("The Gray Sheet" May 25, In Brief). Gene Logic's buy provides "the critical mass and range of technologies necessary to support key aspects of the drug discovery and development process," Gene Logic says